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Q2Substituted hydroxyapatite coatings of
bone implants
Daniel Arcos *ab and Marı́a Vallet-Regı́ *ab
Surface modification of orthopedic and dental implants has been demonstrated to be an effective
strategy to accelerate bone healing at early implantation times. Among the different alternatives, coating
implants with a layer of hydroxyapatite (HAp) is one of the most used techniques, due to its excellent
biocompatibility and osteoconductive behavior. The composition and crystalline structure of HAp allow
for numerous ionic substitutions that provide added value, such as antibiotic properties or
osteoinduction. In this article, we will review and critically analyze the most important advances in the
field of substituted hydroxyapatite coatings. In recent years substituted HAp coatings have been
deposited not only on orthopedic prostheses and dental implants, but also on macroporous scaffolds,
thus expanding their applications towards bone regeneration therapies. Besides, the Q4capability of
substituted HAps to immobilize proteins and growth factors by non-covalent interactions has opened
new possibilities for preparing hybrid coatings that foster bone healing processes. Finally, the most
important in vivo outcomes will be discussed to understand the perspectives Q5of substituted HAp
coatings from a clinical point of view.
1. Introduction
Orthopedic implants improve the quality of life of millions of
patients every year. Due to clinical staff training, new prosthesis
designs, control of sterility and protocols for antibiotic prophy-
laxis, the success rate of orthopedic prostheses has significantly
increased in the last decades. For instance, the success rate of
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at 20 years.1 In the case of titanium based dental implants, the
success rate is very similar.2 Despite these clinical outcomes,
thousands of prostheses and dental implants must be revised every
year. The two most frequent causes for failure are insufficient bone
formation around the implant immediately after implantation,3,4
especially in osteoporotic patients,5–8 and infection.9
Bone implants for load-bearing applications are generally
made of metals such as titanium, Ti6Al4V alloys, stainless steel,
etc., which exhibit appropriate mechanical properties to be
used in the clinic as dental implants and stems of hip and
knee prostheses, plates, screws and other fixation devices. In
the case of endosseous metal components such as dental
implant roots or joint prosthesis stems, the surfaces are com-
monly modified by roughening and/or coating with bioactive
compounds to improve the osteoconductivity. HAp is a calcium
phosphate (CaP) commonly used for the fabrication of coat-
ings, layers or thin films on the surface of prosthetic devices10
to accelerate bone healing at early implantation times. For this
aim, the coating must be biocompatible,11 bioactive12 and
osteoconductive.13 Besides, ASTM and ISO standards require
other properties, namely the presence of a dominant crystalline
phase that prevents fast coating dissolution, the presence of an
amorphous phase that promotes early osteointegration without
losing stability, a programmed dissolution rate of the crystal-
line phase (commonly HAp), an elemental composition match-
ing the mineral phase of bone and strong implant adhesion to
prevent mechanical failures under load-bearing conditions.14,15
Currently, just a few coatings fulfil these requirements and only
calcium phosphate bioceramics fabricated by plasma spraying
are clinically approved for orthopedic coatings and commer-
cially available.
Substituted HAp coatings have arisen as a very promising
alternative to conventional CaP coatings. Ionic substitutions
are aimed at providing additional properties to HAp such as
osteoinduction or antibiotic activity. Therefore, substituted
HAp coatings would be produced not only for accelerating
biomechanical fixation but also for providing solutions in some
pathological scenarios such as infection and osteoporosis.
Currently, the field of substituted HAp coatings has become
an ever-growing research field, mainly due to the variety of
elements and ions with therapeutic effects discovered during
the last 50 years.16 Moreover, HAp exhibits a crystalline struc-
ture that easily allows ion incorporation by substitutive and
interstitial mechanisms. These facts have opened new scenar-
ios where coatings play an active role in the treatment of
pathologies, in addition to accelerating bone healing at early
implantation times. In association with the recently developed
additively manufactured metallic scaffolds, substituted HAp
coatings are also expanding the clinical applications of metallic
implants from their conventional substitutive functions
towards bone regeneration purposes. Recently, the combi-
nation of substituted HAp with nanostructures has also opened
new possibilities in the field of coatings for orthopedic
purposes.17–19
This review is devoted to the performance of substituted
HAp coatings for orthopedic and dental devices. Beginning
from the bioinorganic characteristics of the substituents and
the most frequently applied coating methods, the in vitro and
in vivo biological performance are comprehensively reviewed
and analyzed.
2. Crystalline structure of
hydroxyapatite and ionic substitutions
Stoichiometric HAp is one of the most important bioceramics
used in dentistry and orthopedic surgery. Its composition,
Ca10(PO4)6(OH)2, is like the mineral component of bone tissue
although there exist important crystal-chemical and micro-
structural differences, depending on the synthesis method.
The structure of HAp can be described as a hexagonal unit cell
with space group P63/m and lattice parameters a = 9.432 Å and c
= 6.881 Å, having one formula Ca10(PO4)6(OH)2 per unit cell
21
(Fig. 1). The OH ions and four Ca2+ ions at Ca(1) sites lie along
columns parallel to the c axis. The OH are sited along the c
axis and the O–H bond direction is parallel to it, without
straddling the mirror planes at z = 1/4 and 3/4. The remaining
six Ca2+ ions, positioned at Ca(2) sites, are associated with the
two OH groups in the unit cell, where they form triangles
perpendicular to the OH. The phosphate tetrahedrons form
the remaining basic structural unit of HAp.
The bioactive behavior of stoichiometric HAp can be
improved by introducing substitutions in both the cationic
and anionic sublattices.22 The cations can exhibit the same
oxidation state as Ca2+, such as Sr2+, Pb2+, Mg2+, etc.,23–26 and
anions the same oxidation state as OH, such as F or Cl.27,28
Ionic substitutions with different oxidation states are also very
common29–31 and play an important role in the chemical,
structural, and microstructural properties. For example in
biological apatites CO3
2, substitution for PO4
3 (type B) or
OH (type A) is a likely substitution.32,33 In the case of B-type
carbonated HAp (CHAp), single valence cations (Na+ or K+) are
often incorporated in the Ca2+ positions to keep the electrical
balance.34,35
3. Production techniques of
hydroxyapatite coatings
The production techniques of HAp coatings can by classified
into two main groups: physical deposition techniques and wet
chemical deposition techniques.36 Regardless of the coating
technique used, the success or failure of the coating greatly
depends on the previous preparation of the substrate. Surface
cleaning is required to remove dirt, oils and other components
coming from the machining of the prostheses. This cleaning
commonly consists of an ultrasonic bath of ethanol or acetone
and often includes a subsequent acid treatment (etching) and/
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3.1 Physical deposition techniques
Thermal spraying techniques. The most important physical
deposition techniques for the fabrication of HAp coatings are
thermal spraying techniques. They are based on processes in
which the coating materials (or precursors) are heated and
sprayed on the substrate. Depending on the heating method,
thermal spraying includes atmospheric plasma spraying,37
vacuum plasma spraying,38,39 suspension plasma spraying,40
liquid phase plasma spraying,41 high velocity oxy-fuel
spraying42 and gas tunnel type plasma spraying.43
Due to the very high temperatures used in these techniques,
differences between the feedstock material and the deposited
coating are unavoidable. Deposited HAp and substituted HAp
are dehydroxylated and partially decomposed into oxyapatite
(OA) and other CaP phases. In fact, the so named HAp coatings
are commonly multiphase coatings containing amorphous
calcium phosphate (ACP), a or b tricalcium phosphate (a or
b-TCP), OA, HAp and even CaO. In other words, the coating
composition does not depend only on the feedstock material,
but also on the heating and cooling processes undergone
during their permanence within the plasma and cooling ratio.
This multiphasic composition is decisive for the biocompat-
ibility, since the content of more soluble phases such as ACP
determines the stability of the coating. ISO rules determine that
the HAp content shall be more than 95% by mass, whereas the
content of a-TCP, b-TCP, TTCP and CaO shall be less than a 5%
mass fraction. Regarding the coating crystallinity, the HAp
phase shall have crystallinity values not less than 45% with
respect to standard HAp (HAp after calcination at 1000 1C for 15
hours).14
Thermal spraying based techniques produce thick coatings
of several tens of micrometers,44 although the use of a feed-
stock as a solution or suspension can result in thinner coatings
(5 to 10 mm) in comparison with thermal spraying when using
dry powders. For instance, high velocity oxy-fuel spraying, a
thermal spray process developed in the 90s,45 allows the
fabrication of thin films with low porosity and high adhesion,
due to the velocity reached by the powder feedstock (around
800 m s1) when injected into a gas stream produced by the
combustion of a fuel with oxygen.
Electrophoretic deposition (EPD). EPD is a physical coating
method that consists in depositing charged colloidal HAp
particles onto a conductive substrate of opposite charge.46
The HAp particles are suspended in liquid media and subse-
quently deposited by the driving force of a DC electric field, the
substrate being one of the electrodes. The coating thickness
and morphology can be adjusted through the applied voltage,
in such a way that the particle size and amount of deposited
HAp increase with it. After deposition, the implant is com-
monly treated at 850 1C to 950 1C under high vacuum
conditions.47 EPD is a very useful technique for the fabrication
of coatings onto porous structures; however, the main draw-
back is the shrinkage and cracking that often appear during the
sintering process.
Physical vapor deposition (PVD) techniques. PVD techni-
ques, commonly referred to as sputtering techniques, are
among the most widely used methods for the preparation of
HAp coatings. PVD commonly involves the use of a highly
energetic beam of ions or electrons projected onto a CaP target.
Ca2+, PO4
3 and substitution ions are pulled out from the target
surface and deposited onto the substrate. Depending on the
technique used to knock the ions off the target, sputtering
techniques are denoted as pulsed electron deposition (PED) if
the ions are pulled out from the CaP target by means of
collisions with electrons;48,49 pulsed laser deposition (PLD),
or laser ablation deposition50,51 uses a high-power laser beam
to hit a CaP target resulting in a gaseous phase made of atoms,
ions, molecules and clusters, which is moved towards the
substrate as a plasma plume. This approach leads to thin
HAp coatings of 0.05 to 5 mm thickness52,53 and the heating
of the substrate is required for crystallization. Radio-frequency
magnetron sputtering (RFMS) produces coatings in large areas
and with a large variety of morphologies. It is based on PVD in

























Fig. 1 The unit cellQ6 of hydroxyapatite projected along the a axis (left) and along the c axis (right) showing Ca1, Ca2, tetrahedral phosphates and hydroxyl
sites. Ionic substitutions with potential therapeutic effects are indicated (bottom).
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chamber as a gas. The particles are ionized by powerful
magnets and the charged material aligns on the substrate to
form the coating.54,55 For the specific case of CaP coatings,
Surmenev established the parameters that directly affect the
quality of the coating, namely the discharge power, working
pressure, substrate temperature, flow rate, deposition time and
the subsequent thermal treatment.56 Since Cooley et al. used
for the first time this approach to prepare CaP coatings,57 RFMS
has been used to produce different biocompatible coatings on
several substrates;58,59 matrix-assisted pulsed laser deposition
(MAPLE) was introduced as an alternative to PLD for the
synthesis of thermally unstable compounds, mainly organic
coatings. This technique has also shown some advantages for
the fabrication of inorganic coatings as well.60 In the case of
CaP coatings, MAPLE has shown very interesting results for the
fabrication of thermally unstable octacalcium phosphate
coatings,61 organic–inorganic composites62 or even CaP coat-
ings containing drugs.63
3.2 Wet chemical deposition techniques
The different chemical deposition approaches are character-
ized by occurring from solutions or suspensions. During the
coating process, the chemical composition of the feedstock
material changes by means of a chemical reaction, resulting in
a different compound at the end of the coating production.
Chemical deposition processes occur at moderate temperature
and are mostly governed by the solution supersaturation, pH
and temperature, although the addition of nucleators, inhibi-
tors, etc. allows the control of the coating characteristics. In this
approach, the previous conditioning of the substrate surface is
compulsory. For instanceQ7 , the coating of Ti implants commonly
requires acid or alkaline pre-treatment to form a rich Ti–OH
layer, which facilitates the subsequent calcium phosphate
nucleation and growth.64
Chemical vapor deposition technique (CVD). CVD consists
in the exposure of the substrate to volatile precursors that react
or decompose on the surface. CVD has been used to prepare
CaP-based coatings on metallic substrates65 demonstrating
potential for controlling the crystal phase and microstructure
and providing well-adhered coatings even on complex-shaped
metal substrates.66
Biomimetic deposition techniques. Biomimetic deposition
consists in mimicking natural manufacturing methods to gen-
erate artificial bone-like HAp, which can be used to improve the
osteointegration of dental and orthopedic implants. The most
common process consists in the crystallization of nonstoichio-
metric carbonate-substituted hydroxyapatite (C-HAp) from
simulated physiological solutions at low temperature
conditions.67 The biomimetic HAp crystallization takes place
through the nucleation of ACP or OCP, which subsequently
maturates into substituted and calcium-deficient hydroxyapa-
tite (CDHAp). Like other chemical deposition techniques, bio-
mimetic deposition commonly requires substrates with OH
containing surfaces such as Si–OH, Ti–OH, Zr–OH, Nb–OH etc.,
which can be easily obtained by acid or alkaline treatments.
When these activated substrates are soaked in solutions where
the ionic product overcomes the solubility constant (Kps) for
HAp (for instance simulated body fluid, SBF), the hydroxyl
groups promote CaP nucleation and subsequent crystallization
into apatite like-phases. This technique allows for the co-
deposition of other biological substances, since the coating
process is carried out using mild conditions of pH and
temperature.68,69
Sol–gel method. The sol–gel method consists in the prepara-
tion of a colloidal liquid suspension ‘sol’ by means of the
hydrolysis and condensation of the CaP precursors (commonly
phosphorous alkoxides and inorganic calcium salts).70 Aided by
the presence of an acid or basic catalyst, the sol undergoes a
transition into a solid ‘gel’ that is deposited on the substrate.
Procedures such as dip-coating have proven to be very useful for
the control of the thickness, morphology and homogeneity of
the coatings.71,72 Dip-coating consists in the immersion of the
substrate into a solution containing the coating precursors. In
the case of HAp or substituted HAp coatings, the precursors are
soluble salts of the cations (such as Ca(NO3)24H2O) and
alkoxides of the anions, for instance triethyl phosphite
P(OCH2CH3)3 (TIP) and tetraethyl orthosilicate Si(OCH2CH3)4
(TEOS) solutions in the case of silicon substituted
hydroxyapatites (Si-HAp).73 The substrate is soaked at a
constant speed and the coating is deposited during the
substrate withdrawal. The pulling up speed determines the
coating thickness: the faster the withdrawal the thinner the
coating, although several immersions can be performed in
order to obtain thicker coatings.
Electrochemical deposition (ECD). The ECD technique uses
a supersaturated aqueous electrolyte solution of Ca2+ and
PO4
3 ions in contact with platinum (anode) and metallic
implant (cathode) electrodes connected to a current
generator.74 The electrochemical reactions occurring around
the cathode lead to a pH increase and subsequent calcium
phosphate nucleation and growth occurs. This approach can be
carried out under ambient conditions75 or higher temperatures
in an autoclave76 and thin coatings of less than 1 mm with
uniform structures can be obtained. The main drawback is the
large volume of electrolyte solution required, the hydrogen gas
produced, which can lead to inhomogeneities, and the limita-
tion to coat only conductive materials.
Micro-arc oxidation (MAO). MAO is a wet chemical techni-
que that combines electrochemical oxidation with high voltage
treatment in solutions containing calcium, phosphate and
precursors of other ions as inorganic salts.77,78 MAO has been
used to prepare substituted HAp coatings on metallic implants
and is a suitable approach to obtain porous and rough ceramic
surfaces.79
Electrospray deposition (ESD). ESD involves the formation
of an aerosol from a solution of calcium and phosphorous
solution in a volatile organic component. This aerosol is
sprayed through a nozzle over the substrate under the presence
of a high voltage.80 The coating characteristics can be tuned by
controlling the precursor solution (mainly pH and concen-
tration) and deposition parameters such as the temperature
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dense and homogeneous surfaces, coatings produced by ESD
require a further annealing stage.
Drop on demand microdispensing (DODMD). DODMD is an
additive manufacturing process which has been successfully
used for fabrication of substituted hydroxyapatite coatings.81 In
this method, a suspension of a previously synthesized biocera-
mic is dispensed drop by drop by a micro-valve assisted by a
pneumatic system. DODMD allows for depositing both organic
and inorganic materials and living cells. Moreover, DODMD
employs a layer-by-layer approach enabling the fabrication of
multi-layered functionally graded coatings.
4. Substituted hydroxyapatite coatings
4.1 Cationic substitutions in hydroxyapatite coatings
Zinc-substituted hydroxyapatite (Zn-HAp) coatings. Zinc
(Zn) is the second most abundant essential element in humans.
In an average adult there are about 3 g of Zn and it is widely
accepted that it is essential for all living beings. Zn enzymes
catalyze the metabolic conversion (synthases, polymerases,
ligases, and transferases) and the degradation (hydrolases) of
proteins, nucleic acids, lipids, porphyrin precursors and other
biologically important compounds. In addition to the catalytic
function, Zn has a structural function in different proteins and
participates in processes related to cell division, nucleic acid
replication and gene transcription. Consequently, Zn is essen-
tial for growth, development and differentiation for all species,
and particularly for humans. Zn deficiency leads to serious
pathological effects, particularly a significant weakening of the
immunological system.
Zn is only present in bone as a trace element. However, the
incorporation of Zn2+ cations in HAp structure has attracted the
interest of many researchers. Zn2+ isoelectrically substitutes for
Ca2+, resulting in the decrease of the lattice parametersQ8 a and c
of. This is due to the difference in ionic radius between Zn2+
(0.074 nm) and Ca2+ (0.099 nm),82 favoring the Ca(2) over the
Ca(1) sites.83 Zn2+ cations can incorporate in the HAp structure
in a limited amount (about 20 atom%).84
Several authors have stated that Zn stimulates bone for-
mation by activating proliferation and differentiation of
osteoblasts.85,86 Zn-HAp has also shown antibacterial proper-
ties against both Gram and Gram+ bacteria. HAp doped with
less than 1% of zinc ions has evidenced effective bioactivity and
antibacterial properties.87,88
Zn-HAp coatings have been fabricated by different techni-
ques including plasma spraying,89 EPD,90 sol–gel spin coating91
and magnetron sputtering.92 The fabrication method deter-
mines the Zn distribution within the coating. For instance,
whereas the EPD method yields homogenous Zn-HAp coatings,
magnetron sputtering produces Zn-HAp coatings with higher
Zn concentration on the film surface.93 Zn-HAp coatings pre-
pared by electrochemical deposition have been also proposed
for enhancing the corrosion resistance of commercially pure
titanium (CP-Ti) substrates.94 These coatings were deposited
together with a calcium silicate by adding SiO2 nanoparticles to
the electrolyte solution. Certainly, the Zn-HAp/calcium silicate
coating enhanced the corrosion resistance of CP-Ti, but this
effect could not be attributed exclusively to the presence of Zn
within the HA structure due to the presence of a secondary
phase in the coating.
The optimal amount of Zn to obtain appropriate biological
outcomes has been considered by different authors. Webster
et al. showed that Zn amounts as small as 1.3% cause an
increase in osteoblast responses.95 This high response to small
amounts of Zn2+ is very convenient, as the amount of Zn2+ that
can be incorporated is limited, especially when high tempera-
ture methods are used. For instance, Zn-HAp coatings prepared
by solution precursor plasma spraying easily decompose in the
presence of Zn, resulting in the stabilization of a-TCP.96 Zn-
HAp coatings exhibit antibacterial properties in a Zn-dose
dependent manner, which has been attributed to Zn2+ release
to the local environment.
The presence of Zn2+ cations partially inhibits the nuclea-
tion and growth of a newly formed apatite layer, commonly
occurring when HAp is in contact with SBF. This fact could be
explained in terms of inhibition of the Ca2+ and PO4
3 inter-
actions due to the presence of Zn2+ on the surface.97 Zn-HAp
coatings containing 7% Zn2+ substitution have been prepared
by the hydrothermal method.98 Despite this decrease of in vitro
bioactive behavior, the adhesion, proliferation and spreading
studies evidenced that human osteoblast cells show better
responses on Zn-HAp compared to pure HAp coatings. Since
the hydrothermal method involves Zn-HAp precipitation from
Zn2+ containing solutions, this coating is significantly thinner
than pure HAp coatings (18 mm and 100 mm for Zn-HAp and
HAp, respectively). However, scratch tests showed similar cri-
tical loads for both coatings, indicating that hydrothermally
fabricated Zn-HAp prepared by this method presents good
adhesion to titanium surfaces.
Despite the efforts for increasing the amount of Zn within
HAp structure, there is not in vivo evidence of the positive effect
of Zn-HAp coatings and the effects of Zn2+ cation release in
bone marrow are controversial. Sogo et al. prepared Zn sub-
stituted b-TCP/HA composites and determined with ex-vivo
studies an optimal Zn content of 0.316% in weight to promote
bone formation.99 Subsequently, the same group carried out
in vivo studies evidencing that incorporation of Zn in b-TCP
resulted in both favorable and unfavorable results.100 Certainly,
this material showed enhanced bone apposition to the implant
surface. However, long-term studies also evidenced increased
bone resorption in the medullar cavity area. These results
indicate that Zn2+ release from CaP could be only clinically
applied with small amounts of Zn2+ or carefully selecting
implantation sites without exposure to bone marrow.
Increasing the bonding strength between HAp coatings and
the substrate has been another topic of interest in the field of
substituted HAp coatings. Certainly, the phase composition
and the coating morphology play a fundamental role in the
bone strength magnitude, and these features are strongly
dependent on the coating method, especially at the sub-
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evidenced that the presence of certain ionic substitutions can
enhance the bonding strength for certain coating–substrate
pairs. Zn substitution modifies the interfacial properties
between HAp coatings and Ti substrates, mainly due to the
influence of Zn2+ ions on the preferential HAp crystal growth
along the [0 0 2] and [2 1 1] directions.101
Copper-Substituted hydroxyapatite (Cu-HAp) coatings. Cop-
per is an essential trace element for most living organisms. The
amount of Cu in a 70 kg adult human is about 0.15 g. Cu is a
fundamental component in the catalytic site of several redox
enzymes and its presence is basic for the normal development of
cellular respiration, defense against free radicals, synthesis of
melanin, synthesis of conjunctive tissue and iron metabolism.
Cu deficiency is a serious problem especially in newborns,
resulting in anemia, bone anomalies and fractures in those
cases with acute deficiency. On the other hand, an excess of
copper results in toxicity by accumulation in the liver and brain.
In those patients with Wilson syndrome, Cu accumulation can
lead to the progressive destruction of liver and nervous tissue.
Cu2+ cations have been incorporated in HAp bone grafts to
provide antimicrobial and bactericidal activity,102 angiogenic
potential103 and the capability to stimulate the activity of
osteoblastic cells.104 Several authors have proposed a Cu2+ for
Ca2+ substitution mechanism for the incorporation into the
HAp structure.105,106 However, recent studies have shown that
an interstitial mechanism takes place during Cu2+ incorpora-
tion. For thermal treatment below 1100 1C, Ca10Cux(-
PO4)6(OH)22xO2x is formed with x o 0.1 and Cu2+ cations
occupying the interstitial 2b Wyckoff position. Above 1100 1C,
Cu rich HAp can be synthesized with the presence of Cu+ and
Cu2+ also following an interstitial mechanism.107 The potential
advantages of Cu-rich HAp have been questioned due to the
cytotoxicity of this cation. A high content of Cu precursors can
result in the formation of CuO, which seriously compromises
cell viability. There are very few studies of Cu-HAp coatings, as
most of the prepared Cu-HAp have been obtained as powders or
pieces. Cu-HAp coatings have been prepared by plasma spray-
ing, but this coating did not show any advantage compared to
non-substituted HAp.108 More recently, Cu-HAp coatings have
been prepared by solution precursor plasma spraying on sand-
blasted stainless-steel substrates.109 However, even after opti-
mizing the coating parameters, impure Cu-HAp coatings were
obtained mixed with CaO and CuO. No biological evaluation
was carried out in this study.
In Cu-HAp coatings prepared by PLD on Ti6Al4V
substrates,110 Cu2+ for Ca2+ substitution mechanisms were
described, although interstitial incorporation could not be
discarded. Cu2+ cations were largely incorporated in the HAp
structure and introduced a high degree of crystal-chemical
modifications, including a reduction of the carbonate presence
in the coatings. However, these differences were not reflected in
the biological behavior, since Cu-HAp elicited almost identical
behavior to Zn-HAp coatings with respect to pre-osteoblast
proliferation and antimicrobial activity.
Silver-substituted hydroxyapatite (Ag-HAp) coatings. Silver is
a metal element absent in the human body, unless accidental
contamination occurs. Ag does not play any essential role for
mammals since it is not found in the active site of any enzyme
or exerting structural functions in cells or tissues. However, the
incorporation of Ag+ in bioceramics has been widely studied in
recent years. Ag+ is an effective antimicrobial agent and its
inclusion in HAp coatings is used to prevent orthopedic and
dental implant infections. The antimicrobial activity of Ag+ is
related to its capability to bind to microbial DNA, preventing
bacterial replication, and interacting with sulfhydryl groups of
the metabolic enzymes of the bacterial electron transport
chain.111
Ag-HAp coatings with proved antibacterial effects have been
prepared by PLD,112 co-precipitation,113 plasma spraying,113–115
magnetron sputtering116 or sol–gel methods.117 In vivo studies
have demonstrated the antibacterial properties of thermally
sprayed Ag-HAp coatings.118 These authors proposed a subcu-
taneous model in rats to test the antimicrobial activity of
thermally sprayed Ag-HAp coatings on titanium discs. The
coating was evaluated against methicillin-resistant S. aureus
isolated from the blood of a septic patient. Although this study
could not evidence the intramedullary antibacterial effects in
bone, as would be desirable for an orthopedic implant, it is one
of the few in vivo studies developing an infection model to
assess the antimicrobial activity of substituted HAp coatings.
More specifically, it could be demonstrated that Ag-HAp coat-
ings exhibit a high bactericidal effect even with a large number
of bacteria inoculated (around 106 CFU) in the subcutaneous
pocket. Plasma sprayed Ag-HAp coatings prepared on titanium
substrates108 have also evidenced that these coatings are highly
hydrophilic, show low resorbability in vitro and exhibit excel-
lent antibacterial effects against S. aureus.
Ag+ ions also exert a significant influence on the bonding
strength. In the case of Ag-HAp on Ti substrates, the presence
of Ag seems to improve the adhesion strength for electrospray
deposited coatings,119 although contradictory results were
obtained by Yan et al., who observed a decrease of bonding
strength for Ag-HAp coatings prepared by a similar method.120
From a theoretical point of view, Ag+ (and also Zn2+ ions)
positively influences the adhesion between HAp and a-Ti
substrates. First-principles electronic structure calculations121
predict that the work of adhesion at the interface between the
(0001) planes of HA and a-Ti reaches larger values for Zn and Ag
doped HAp than for stoichiometric HA/Ti interfaces. The
analysis of the electronic structure of the calculated model
indicates that doping with Ag or Zn increases the charge
transfer between HAp and Ti slabs, reinforcing Ti–O bonds
and driving the HA/Ti interface system to be more metallic.
Magnesium-substituted hydroxyapatite (Mg-HAp) coatings.
Mg is an essential element with high presence in the human
body. A 70 kg adult human contains about 30 g of Mg. The
biological role of Mg in vertebrates is analogous to Ca in the
formation of the skeleton and stabilization of cell membranes.
Regarding the enzymatic activity, Mg is an essential factor for
phosphate group transference reactions and in many non-
oxidative nucleic acid cleavage reactions by nucleases. Mg
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mental and physical capabilities, which is a consequence of
insufficient energy production due to anomalies in phosphate
transference reactions.
Mg is found in natural HAp partially replacing calcium. Mg2+
ions inhibit HAp crystallization, avoiding the formation of large
crystals and promoting the formation of more apatite nuclei.
This activity is very important as nanocrystalline bone apatites
are required for the appropriate bone formation–resorption
turnover carried out by bone cells. Mg2+ deficiency affects bone
growth, reduces bone density and leads to bone fragility.122
These facts have encouraged different groups to carry out the
artificial preparation of Mg-HAp in different forms, including
coatings, where concentrations of Mg around 1% wt have
shown optimal properties.123 Mg-HAp coatings have been pre-
pared by thin film deposition techniques such as magnetron
sputtering, PLD, MAPLE, PED,124 and plasma spraying,125 as
well as by electrochemical deposition methods.126,127 Mg-HAp
coatings prepared by both physical deposition and electroche-
mical methods show a crystallinity decrease and heterogeneous
distribution of the Mg content, forming Mg-rich areas. In vitro
cell culture tests have evidenced that osteoblasts preferentially
concentrate, attach and grow in these areas, evidencing the
positive effect of Mg on bone forming cells.
Electrochemical deposition of calcium orthophosphates
commonly involves hydrogen gas production, which often leads
to heterogeneous coatings with large pores caused by
bubbles.128 Mg2+ incorporation as a soluble salt leads to a
decrease in both the pore size and pore volume in Mg-HAp
coatings, with preferentialQ9 Mg accumulation in the regions
outside. Although these features could provide better corrosion
resistance, Mg-HAp coatings prepared by electrochemical
deposition showed similar parameters to those observed for
non-substituted HAp.127
Strontium-substituted hydroxyapatite (Sr-HAp) coatings. Sr
is considered as a non-essential element that is present in the
human body. About 0.14 g of Sr is contained in an average
human adult. Sr is mainly found in the mineral phase of bones,
especially in those regions where bone turnover is more
active.129 The incorporation of Sr into CaPs has been motivated
by its inhibitory effect on bone resorption and the improvement
of bone formation in osteoporotic patients.130 Several studies
have demonstrated that Sr2+ for Ca2+ substitution in CaPs
increases the activity of osteoblasts and inhibits osteoclast
proliferation.131,132
Contrarily to Mg2+ and Zn2+, Sr2+ has a larger ionic radius
than Ca2+ (112 vs. 99 pm), which leads to an enlargement of the
HAp unit cell and causes an increase of the cell volume. This
crystalline distortion also favors the incorporation of carbonate
and HPO4
2 anions when Sr-HAp is prepared by low tempera-
ture synthesis methods.133 Sr2+ can totally substitute for cal-
cium in the HAp structure.134
Sr-HAp coatings have been fabricated on
poly(etheretherketone) (PEEK) by PED.133 Amorphous Sr doped
CaP was deposited at room temperature and a subsequent
annealing treatment as low as 130 1C was enough to obtain
homogenous and Sr-HAp coatings with a Sr/Ca ratio very
similar to the target composition. Interestingly, coatings contain-
ing high amounts of Sr2+ exhibit lower wettability than non-
substituted HAp coatings. This fact has been also observed for
Sr-HAp coatings prepared by plasma electrolytic oxidation (PEO).
Teng et al.135 observed that Sr-HAp coatings on Ti substrates
increased the wettability for a Sr2+ : Ca2+ molar ratio of 0.12,
whereas Sr2+ : Ca2+ of 0.25 led to a significant decrease of
wettability. The low wettability of Sr-HAp with high Sr content
would provide excellent protection against corrosion for metallic
substrates.136 However osteointegration strongly depends on the
protein–surface interactions, which are regulated by hydrophili-
city. In a recent study, Wu et al.137 evidenced the positive effect of
electrodeposited Sr-HAp coatings on the stability of Mg alloys, by
means of protecting them from corrosion and enhancing cell
proliferation. However, for those coatings with the highest Sr
content, a lower expression of osteogenic markers Col-1, Runx2
and ALP was observed. These facts indicate that the Sr-HAp
coating shows an optimal substitution degree that would result
in the highest HAp content, hydrophilicity and cell viability. As
expected, the coating procedure strongly influences the optimal
Sr/Ca ratio for in vitro cell response. In this sense Sr-HAp coat-
ings prepared by a pre-calcification method on an anodized
titanium plate exhibited the best in vitro pre-osteoblast cell
response for a Sr/Ca + Sr molar ratio of 0.5.138
Roy et al. prepared Sr and Mg doped HAp coatings (1 wt% in
both cases) on Cp-Ti by inductively coupled radio frequency
plasma spraying.139 The coatings exhibited adhesive bond
strength similar to non-doped HAp (around 17 MPa). Despite
the minimal effects that Sr and Mg had on the physical proper-
ties, the presence of these substituents led to significant
improvements in cell–coating interactions. Sr-HAp coatings
induced better cell attachment and proliferation of human
fetal osteoblasts as well as higher expression of ALP. The
incorporation of Mg also resulted in biocompatible coatings,
albeit it did not lead to any improvement with respect to pure
HAp coatings.
Different studies carried out with highly substituted Sr-HAp
point out an undeniable inhibitory effect on osteoclastogenesis,
but a limited benefit to the osteoblast function, which depends
on the Sr amount. A very interesting alternative has been
recently proposed by Boanini et al. consisting in the fabrication
of gradient coatings of calcium phosphates substituted with
different cations.140 By means of Combinatorial Matrix Assisted
Pulsed Laser Evaporation (C-MAPLE), Sr-HA/Zinc b-TCP coat-
ings were prepared with a homogeneous distribution of the two
phosphates. This strategy consists in combinatorial coating
fabrication aimed to obtain synergies from the osteogenic
properties of Zn and the osteoclasts inhibitory effects of Sr.
These authors could demonstrate that the cell response can be
modulated as a function of compositional intermixing of both
substituted calcium phosphates. The osteoblast activity
improved as a function of the Zn b-TCP content, whereas a
higher presence of Sr-HAp led to the inhibition of osteoclasto-
genesis without affecting the osteoblast biocompatibility.
Other substituted hydroxyapatite coatings (Co2+, Na+, Mn2+,
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are some other substituted HAp coatings that are mentioned in
just a few papers, so that a detailed description and discussion
are not always possible. However, there are some examples
including substitution with essential cations or rare earths
which have shown interesting results that deserve to be
mentioned.
Cobalt is an essential trace element with a very specific
function in humans. Among the elements of the first transition
series, Co is the leastQ10 abundant in the Earth’s crust and sea
water. In fact, vitamin B12 and its derivatives are the only Co
containing compounds with biological activity. A 70 kg adult
human contains about 0.003 g of Co, being the second least
abundant essential element after molybdenum. However, sev-
eral studies involving Co-doped bioceramics141–143 point out an
angiogenic effect of Co2+, which could favor the neovascular-
ization of newly formed bone by inducing hypoxia conditions.
These studies have been commonly done on bulk and powder
materials, but studies on Co-HAp coatings are very scarce. Co-
HAp coatings have been recently prepared by electrodeposition
on Ti22Nb6Zr alloy.144 Although no biological effects were
evaluated, this article evidences the improvement of corrosion
resistance with the incorporation of Co2+. This effect is
explained in terms of the higher particle aggregation under-
gone by HAp particles during electrodeposition in the presence
of Co2+. Consequently, the electrodeposited Co-HAp coatings
are denser and less porous than the undoped HAp coating, thus
providing corrosion protection to the metal alloy.
Enhanced corrosion protection has been also obtained with
sodium substituted hydroxyapatite (Na-HAp) coatings prepared
by electrophoretic deposition.145 In this case, the coating is
made of a composite containing Na-HAp and chitosan that is
deposited on 316L stainless steel previously coated with poly(O-
phenylenediamine). This coating showed in vitro bioactive
behavior and high corrosion resistance in SBF. However, no
conclusion could be obtained regarding the presence of Na+ in
the ceramic component, since the required comparison with
non-substituted HA was not carried out.
Manganese is an essential trace element that shows the
most potent capacity for binding to integrins.146 Mn occupies
the active site of several metalloenzymes and acts as a Lewis
acid (as Mn2+) catalyzing hydrolytic reactions and as a redox
catalyzer when Mn exhibits high oxidation states. A 70 kg adult
human contains about 0.02 g of Mn. Several studies have
endeavored to use Mn to enhance the osteoconductivity of Ti
substrates by means of its potent cell adhesion-promoting
effect.147–149 These coatings supported a better cell response
with increased viability, proliferation and ALP activity in osteo-
blastic cells compared with bare Ti or untreated b-TCP film.
More recently, Mn-HAp coatings have been produced by elec-
trodeposition on ZnO coated stainless steel.150 This bilayer
coating improved the corrosion resistance, mechanical proper-
ties, and metal ion leach-out performance as well as the in vitro
bioactivity and biocompatibility. However, Mn2+ does not
always provide beneficial effects when it is associated with
other coatings different from calcium phosphates. Park et al.
studied the effects of Mn incorporation into a titanium oxide
coating on titanium.151 These authors demonstrated that Mn
incorporation, instead of providing biological benefits,
impaired cell behavior by decreasing cellular attachment,
spreading, proliferation, ALP activity, and osteoblast phenotype
gene expression compared with the bare Ti surface. This
apparently contradictory observation could be explained in
terms of the different kinetic release of Mn ions from the CaP
coating and Ti oxide layers, which would differ because of the
differences in biodegradation rate.
Yttrium substituted HAp (Y-HAp) coatings have been
proposed to improve osteoblast (or bone-forming cell) function
over undoped HA.152 Based on the enhancement of the
mechanical properties and conductivity in different ceramics,
Y was incorporated in HAp powders and deposited on titanium
substrates. Greater amounts of calcium deposition by osteo-
blasts cultured on Y-HAp coatings were observed compared
with undoped plasma-sprayed HA coatings.
HAp doped with rare earths has gained interest in recent
years. For instance, Ce3+ or Ce4+ substitutions in HAp have
shown antimicrobial activity.153 Recently, cerium-doped hydro-
xyapatite (Ce-HAp)/collagen coatings have been prepared by
means of a biomimetic process on Ti substrates.154 In this
case, Ce4+ was added as Ce(SO4)24H2O with a final Ce4+
concentration as low as 0.5% in a supersaturated solution of
CaCl2 and NaH2PO4, thus maintaining a cerium concentration
within the therapeutic range.155 The Ce-HAp coatings so
obtained showed 92.61 and 73.59% bactericidal ratios for
E. coli and S. aureus, respectively, indicating a higher efficiency
against Gram-negative bacterial strains. No cytotoxicity studies
were carried out so the information about their potential
application in biological systems is very restricted. Table 1
summarizes the most relevant studies carried out on cation-
substituted HAp coatings and the enhanced biological function
observed in vitro.
4.2 Anionic substitutions in hydroxyapatite coatings
Silicon-substituted hydroxyapatite (Si-HAp) coatings. Silicon
is an essential trace element for most living organisms. A
human adult of 70 kg contains about 1.4 g of silicon. The
unique soluble Si form in physiological conditions is silicic
acid, Si(OH)4, which can be dissolved up to 2 mM at pH = 7. The
essentiality of Si for animal life was established by Carlisle157 by
means of the determination of deficiency symptoms in rats and
chickens fed with silicon depleted diets,156 demonstrating that
Si deficiency led to serious effects on bone growth and defective
formation of connective tissue. Silicon or silicates substitute for
phosphorus, or phosphates, with subsequent charge
imbalance.158 Although the amount of Si that can be incorpo-
rated into HAp ranges between 0.1 and 0.5 wt%,159–162 Si-HAps
have evidenced higher bioactive behavior compared to non-
substituted apatites.163–167
Si-HAp coatings have been prepared by magnetron
sputtering.168 Since the Si substitution is very limited, HAp
and Si were sputtered from different targets instead of a single
Si-HAp one, yielding a layer of Si-HAp of 0.7 mm in thickness
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culture studies showed that Si-HAp thin coatings exhibited
high bioactivity and biofunctionality. Attachment and growth
of human osteoblast-like (HOB) cells was observed during the
culture period, with more formation of extracellular matrix
compared to the uncoated titanium substrate, although no
comparison was established with pure HAp coatings. The same
research group have carried out the preparation of Si-HAp
coatings comparing the influence of the Si content: 0.8 wt%,
2.2 wt%, and 4.9 wt% on Ti to evaluate the long-term in vitro
biocompatibility effects of these coatings in vitro.169,170 HOB
cells showed improved adhesion on the coated surfaces with
increasing Si content and developed mature cytoskeletons with
well-defined actin stress fibers in the cell membranes. How-
ever, the reactivity provided by Si in the Si-HAp with the highest
substitution resulted in fast dissolution that hindered the
initial cell attachment, concluding that a Si content of 2.2
wt% would be the best substitution degree to improve the
bioactive behavior of HAp thin films.
Surmeneva et al. have widely studied the microstructural
characteristics of Si-HAp prepared by magnetron
sputtering.171–173 The microstructure and coating composition
can be controlled by changing the bias voltage from 0 V to 50
and 100 V.172 For instance, the coating thickness decreases
with the magnitude of negative bias, whereas the Ca/P and Ca/P
+ Si ratios increase. Anyway, all the coatings exhibited good
biocompatibility with respect to MG-63 osteoblast cells. Silicon
incorporation also exerts an influence on the mechanical
properties of magnetron-sputtered Si-HAp.173 The nanohard-
ness and elastic modulus decrease as a function of Si content
due to microstructural modifications derived from silicon
incorporation. In addition, the adhesion behavior is also influ-
enced by Si substitution. Whereas coating failure occurred due
to low cohesion in non-substituted HAp coatings, Si-HAp with
1.2 at% deformed plastically without crack formation and a
mixed elastic–plastic behavior was observed for the Si-HAp
coating with 4.6 atom% of Si.
Si-HAp coatings have been also successfully prepared by
PLD,174 sol–gel chemistry followed by dip coating,175 spin
coating,176 electrochemical deposition using electrolytes con-
taining Na2SiO3 as a silicon source
177,178 and by means of
hydrothermal treatment with metasilicic acid, H2SiO3, of a
previously pure HA coating prepared by CVD methods,179 being
one of the most widely investigated substituted HAp coatings.
Fluor Q11-substituted hydroxyapatite (F-HAp) coatings. Fluor is
an essential trace element with a presence of 2.6 g in a 70 kg
adult human. Although essential, there is not much knowledge
about the biological functions of F and its biochemical activity
is not well defined. Most of the F content is in the skeleton
and teeth where it isoelectronically substitutes for OH in HAp.
F anions are also found in extracellular fluids at very low


























Table 1 Cation-substituted HAp coatings and the enhanced biological function observed with in vitro studies
Coating Function Substrate Fabrication method Ref.
Zn-HAp Osteoblast function Titanium, Ti6Al4V Plasma spraying 89 and 96
Corrosion resistance Ti-Coated silicone Electrophoretic deposition 90
Bactericidal Silicon Sol–gel spin coating 91
Titanium; silicon Magnetron sputtering 92 and 93
Titanium Electrochemical deposition 94
Titanium Hydrothermal coating 98
Ti6Al4V Pulsed laser deposition 110
Cu-HAp Bactericidal Titanium Plasma spraying 108
Angiogenesis Stainless-steel Plasma spraying 109
Osteoblast function Ti6Al4V Pulsed laser deposition 110
Ag-HAp Bactericidal Titanium, Ti6Al4V Plasma spraying 108 and 113–115
Adhesion strength Titanium Electrospraying 119
Mg-Hap Osteoblast function Titanium Plasma spraying 125
Ti6Al4V Electrochemical deposition 126
Sr-HAp Osteoblast function PEEK Pulse electron deposition 133
Osteoclast inhibition Titanium Plasma electrolytic oxidation 135
Corrosion resistance Magnesium alloy Hydrothermal, electrodeposition 136 and 137
Titanium Radio frequency plasma spraying 139
Co-HAp Angiogenesis Ti22Nb6Zr Electrodeposition 144
Corrosion resistance
Na-HAp Corrosion resistance 316L stainless steel Electrophoretic deposition 145
Mn-HAp Mechanical properties Titanium Pulsed laser deposition 147–149
Corrosion resistance Stainless steel Electrodeposition 150
Y-HAp Osteoblast function Titanium IonTitet 152
Ce-HAp Bactericidal Titanium Biomimetic 154
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The incorporation of F into the HAp structure reduces the
dissolution rate and increases its hardness.180 Certainly, partial
substitution of F for OH ions, which results in
Ca10(PO4)6(OH)2xFx, is a well-known strategy for enhancing
the structural stability and resistance to dissolution with
respect to non-substituted HAp. The lower solubility of F-HAp
allows the preparation of very thin coatings (below 1 micro-
meter) that otherwise would be very unstable under in vivo
conditions, and would result in implant failure by early degra-
dation. F-HAp thin films have been recently prepared by PLD181
producing coatings of 1 mm in thickness, with higher resistance
to dissolution and better cell attachment of human mesench-
ymal stem cells (HMSCs) compared to HAp coatings.
In vitro studies indicate that the F for OH substitution
enhances cell proliferation and reduces bacterial activity.182
Antibacterial properties of F-HAp coatings on stainless steel
substrates have been proposed for the prevention and treat-
ment of peri-implantitis in dental implants.183 The antibacter-
ial property against different pathogens was dependent on the
coating crystallinity, which could be controlled with a post-
hydrothermal treatment. In this sense both low crystalline and
highly ordered crystalline F-HAp coatings reduced the bacterial
viability, although the ordered one also reduced the bacterial
adhesion. This study concludes that F content, rather than
release, is the most influential variable, although the surface
characteristics also have a significant impact on the bacterial
adhesion, as it has been recently demonstrated for nanopat-
terned Ti coatings on orthopedic devices.184
F-HAps coatings have been prepared by different methods
including sol–gel185 or slip coating methods.186 There is some
controversy regarding the positive or negative biological activity
of fluoride with respect to osteoblast cells. Some studies have
shown that osteoblast cells exhibit lower proliferation rates on
fluoridated coatings compared with cells cultured on non-
substituted HAp coatings, pointing out the potential toxicity of
F anions.187 However, the beneficial or detrimental effects of F
in HAp coatings seem to be dosage-dependent. For instance,
electrodeposition can be used for preparing these coatings by
adding NaF into the electrolyte.188 This method is appropriate to
obtain coatings with a thickness of a few microns (around 5
micrometers) and F/Ca ratios as high as 0.125, i.e a nominal
composition of Ca10(PO4)6(OH)0.75F1.25. However, the best bond-
ing strength on titanium substrates, lower dissolution rate and
most appropriate biological activity were obtained for those
coatings with moderate F contents, with substitution for OH
in the range Ca10(PO4)6(OH)0.75–1F1.25–1.
Carbonate-substituted hydroxyapatite (C-HAp) coatings. C-
HAp has been synthesized as powders, grains, pieces and
coatings for bone grafting applications. The interest in C-HAp
arises from the chemical composition of biological apatites
which are non-stoichiometric, Ca-deficient and carbonated.
This ionic substitution contributes to the higher solubility of
biological apatites, compared with the stoichiometric and
highly crystalline synthetic ones. The presence of CO3
2 in
the HAp structure helps to keep constant bone regeneration
through dissolution–crystallization cycles.
C-HAp coatings have been prepared by RF-magnetron
sputtering,189,190 electrophoretic deposition191–193 biomimetic
deposition,194,195 electrochemical deposition,196 pulsed laser
deposition,197 hydrothermal crystallization198 and even by a
hybrid process of plasma spraying and hydrothermal
synthesis.199 Since C-HAp coatings are more soluble than
HAp, they are likely to provide a better osteogenic response,
although the coating stability can be seriously compromised.
Different strategies have been used to overcome this potential
drawback. For instance, C-HAp coatings deposited on Ti sub-
strates by RF-magnetron sputtering200,201 have been obtained
as dense and well adhered films with controlled elemental
composition. B-type C-HAp coatings have been fabricated by
this method with a rough and homogeneous microstructure
that facilitates the development of hMSC, differentiated cells
and bone explanted osteoblasts. The coating adherence was
improved by introducing a buffer layer of CHA1xTix (x = 0–1)
with a chemical gradient between the Ti substrate and the
Ca102x/3(PO4)6x(CO3)x(OH)2x/3 coating. Another strategy for
enhancing the stability of C-HAp coatings is the formation of
composites with biocompatible polymers. Tang et al. prepared
chitosan/C-HAp on Ti6Al4V substrates by electrophoretic
deposition of CaCO3 and subsequent treatment in a phosphate
buffer solution until transformation into C-HAp.192 However,
the coating exhibited numerous cracks and macropores
between C-HAp particles. This drawback was resolved by soak-
ing the sample in a chitosan solution, which filled the cracks
(linking the C-HAp particles) while keeping the pores, which
could positively contribute to osteointegration after
implantation.
The biomimetic method is one of the easiest alternatives for
the preparation of C-HAp coatings. By soaking preconditioned
substrates in highly saturated SBF, C-HAp spontaneously nucle-
ates and grows on the surface, with disregard of the substrate
morphology, as biomimetic deposition is not a line-of-sight
technique. Moreover, the coating roughness can be easily
controlled by the solution concentration and time exposure of
the substrate to the biomimetic solution. Costa et al.194 pre-
pared C-HAp coatings biomimetically deposited on polycapro-
lactone discs from SBFx7 and SBFx10 during periods of 24 and
48 hours. Whereas SBFx7 led to almost smooth C-HAp coatings,
SBFx10 led to micro-rough topographies. All the coatings were
biocompatible with respect to osteoblasts but, interestingly,
different topographies elicited different responses with respect
to osteoclast cells: smooth coatings allowed high osteoclast
resorptive activity whereas micro-rough coatings partially hin-
dered the formation of actine rings. In this way, the biomimetic
technique would produce C-HAp coatings that improve osteo-
conductivity while minimizing osteoclastic resorption.
Other anion-substituted hydroxyapatite coatings. Since the
HAp structure allows for many different substitutions, some
groups have explored other possibilities with less conventional
anions than those reviewed in previous sections. Boron is
considered an essential element for plants, but not for animals.
Although some studies point out several benefits for osteogenic
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accepted as an essential nutrient for humans. B is incorporated
as borate ions by substitution of phosphate. B-HAp coatings
have been fabricated on chitosan scaffolds203 and MC3T3-E1
cell cultures evidenced enhanced proliferation associated with
B release, indicating the potential of these coatings for in vitro
bone tissue engineering applications.
Selenium is a trace essential element for humans. Around 15
mg of Se is found in an average human. Selenium-doped
hydroxyapatite (Se-HAp) coatings have been prepared by several
methods such as PLD204 or biomimetic techniques including
selenite ions in SBF.200 Rodrı́guez-Valencia et al.205 have
hypothesized on the osteogenic, antitumoral and antibiotic
activity of Se incorporated as SeO3
2 anions into the HAp
structure. Coatings with 2.7 at% of Se resulted in significant
osteogenic activity of MC3T3-E1 pre-osteoblasts, a significant
antiproliferative effect on cancerous osteoblasts (MG63), and
antibiofilm properties against S. epidermidis and S. aureus
bacterialQ12 strains (Table 2).
4.3 Co-substituted hydroxyapatite coatings
Co-substitution is a very interesting strategy to optimize the
biological performance of Hap coatings. Taking advantage of the
different ions available for substitution and the variety of biological
effects, the presence of two or more substituents can lead to
synergistic, complementary or compensatory effects that provide
added value to Hap coatings. Combination of cations with anti-
microbial and osteogenic properties is one of the most attractive
options. The antimicrobial efficiency of Ag+ is explained in terms of
inhibition of the bacterial replication process against both Gram-
negative and Gram-positive bacteria.206 However, Ag+ cations also
exhibit toxicity to human cells above a certain concentration, even if
they are incorporated in Hap coatings.207 This toxicity seems to be
related to the affinity of Ag+ to the ALP high affinity metal site and
the incorporation of a second cation able to alleviate the potential
negative effect of Ag+ has been considered. Geng et al. evaluated the
antibacterial effect and biocompatibility of Ag/Sr-Hap hydrother-
mally coated on Ti substrates.208,209 The addition of Sr2+ signifi-
cantly decreases the Ag+ toxicity, in such a way that co-substituted
coatings keep the antibacterial effect with low silver substitution,
while maintaining the proliferation capability of pre-osteoblast
cells. Sr2+ ions seem to counteract the silver toxicity by reducing
the quantity of Ag+ that gets into the cells by competing for binding
sites of specific cellular function and promoting cell differentiation.
The antibacterial effects of Cu2+ can be also limited due to
the potential toxicity of this cation. Due to the small amount of
Cu2+ that can be incorporated and the risk of segregation of
cytotoxic phases,210 more attention has been paid to Cu con-
taining co-substituted Hap coatings. For instance, co-
substitution with Zn2+ provides much better results than single
Cu2+ incorporation into Hap coatings. Cu/Zn-Hap coatings
prepared by electrodeposition on pure titanium substrates
exhibit antimicrobial activity associated with Cu2+ cations,
whereas Zn2+ makes up for the cytotoxicity of Cu2+.211 Zn and
Cu incorporation also led to an increase of corrosion resistance
compared to non-substituted Hap coatings. This could be
associated with the reduced grain size of Cu/Zn-Hap coatings,
which plays an important role in elevating the electron activity
at the grain boundaries and consequently improving the corro-
sion protection. Certainly, these coatings exhibited antimicro-
bial activity against E. coli, but the study could not clearly
assign this effect to Cu2+ or to the concomitant effect of Q13Zn2+
release.
Sr has been also proposed as a secondary substituent to

























Table 2 Anion-substituted HAp coatings and the enhanced biological functions observed with in vitro studies
Coating Function Substrate Fabrication method Ref.
Si-HAp Osteoblast function Titanium Magnetron sputtering 168–173
Osteoinduction Titanium Pulsed laser deposition 174
Mechanical properties Ti6Al4V Dip coating 175
Bonding strength Zirconia Spin coating 176
Mg5Zn0.3Ca, SiC Electrochemical deposition 177 and 178
C/C composite CLVD/hydrothermal 179
F-HAp Structural stability Titanium Pulsed laser deposition 181
Osteoblast attachment Stainless steel Hydrothermal method 183
Stainless steel Sol–gel 185
Zirconia Slip coating 186
Titanium Electrochemical deposition 188
C-HAp Osteoblast function Titanium RF-Magnetron sputtering 189, 190, 200 and 201
Ti6Al4V Electrophoretic deposition 191–193
Polycaprolactone, Ti Biomimetic deposition 194 and 195
TiO2 nanotubes Electrochemical deposition 196
Titanium Hydrothermal method 198
Ti6Al4V Plasma spraying/hydrothermal 199
B-HAp Osteoblast function Chitosan Microwave assisted precipitation 203
Se-Hap Osteoblast function Titanium Pulsed laser deposition 204
Antitumoral Ti6Al4V Biomimetic 205
Bactericidal
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coatings have been prepared by electrodepositon on CP-Ti and
the antibacterial activity and cytocompatibility have been eval-
uated. The lattice parameters of Cu/Sr-Hap were enlarged with
respect to pure Hap, evidencing that Sr2+, with a larger ionic
radius than Ca2+, plays a major role in the crystal changes
occurring in Hap. The coatings exhibited a bactericidal effect
against E. coli (near to 91% inactivation), although the anti-
microbial ratio did not reach the 99% inactivation required to
be considered as antibacterial. Besides, the Cu/Sr-Hap coating
increases the number of viable preosteoblast seedsQ14 compared
to CP-Ti and stimulated the differentiation towards the osteo-
blast phenotype.
Mg/Sr-Hap coatings have been prepared by plasma
spraying.213 This coating exhibited high bonding strength after
subsequent thermal treatment at 500 1C and induced MC3T3-
E1 preosteblast proliferation. Whereas Mg/Sr-Hap coatings
prepared by plasma spraying do not show microstructural
differences with respect to undoped HA, other attempts to
prepare Mg/Sr-HAP by deposition methods yielded different
outcomes. Mg2+ cations influence the microstructure of hydro-
xyapatite coatings, when the fabrication method involves
nucleation and crystallization from liquid solutions. For
instance, Mg/Sr-Hap coatings prepared by electrochemical
deposition indicate that the presence of Mg as a co-dopant
led to less crystalline and irregular coatings, in agreement with
the inhibitory effect of Hap crystallization attributed to Mg2+.214
This fact would question the convenience of incorporating
Mg2+ in Hap when using wet route deposition-based
techniques.
Substitution of Hap with rare earth elements has been a
field of interest in recent decades, mainly due to the potential
capability of Hap to retain radionuclides and be used for
storage of nuclear waste.215 Recently, the use of substituted
Hap with rare earths for biomedical purposes has been inves-
tigated and has opened new alternatives in the field of bone
implants. For instance, samarium (Sm) substitution in Hap has
demonstrated antibacterial activity, improvement of the osteo-
blast performance and also activity asQ15 a radiotherapeutic agent
in preventing caries.216,217 On the other hand, certain rare earth
cations such as Gd3+ improve the mechanical properties and
corrosion resistance in metal alloys.218 Considering these ante-
cedents, Sm/Gd-Hap coatings have been prepared by electro-
deposition on stainless steel substrates.219 Different Sm/Gd
ratios were incorporated in the Hap structure. Sm/Gd-Hap
coatings containing a 1 : 1 Sm/Gd ratio exhibited an intercon-
nected granular structure with uniform coverage, whereas 2 : 1
and 1 : 2 Sm/Gd ratios resulted in heterogeneous coatings made
of agglomerated particles. The main consequence is that Sm/
Gd-Hap coatings with similar contents of rare earths showed
much better protection against corrosion. Besides, Sm provided
antibacterial properties against E. coli and S. aureus together
with high cytocompatibility with respect to MC3T3-E1
preosteoblastic cells.
Co-substituted Hap coatings have been also prepared by
incorporating cations and anions simultaneously. These coat-
ings are mainly prepared by introducing metal cations like
Co2+,220 Zn2+ 221 or Ag+ 222 in F-Hap, because F ions exert a
dose-dependent effect on osteoblast proliferation and osteo-
genic differentiation223 that compensates the toxic effects of
transition metal cations. Birgani et al.220 incorporated F and
Co2+ ions in CaPs prepared by a biomimetic method on the
surface of culture well plates. Although the crystalline phase
formed seemed to correspond to OCP, the incorporation of F
rendered this CaP more apatitic. The incorporation of Co2+ into
the CaP coating upregulates the expression of VEGF and CD31
angiogenic markers of hMSCs compared to CaP without Co2+.
However, Co2+ suppresses the ALP activity and decreases the
expression of bone sialoprotein (BSP), which results in reduced
mineralization of hMSC. The incorporation of fluoride com-
pensated the adverse effects of Co2+, favoring osteogenesis
while keeping the angiogenic effect.
Zn/F-Hap coatings have been successfully fabricated by ED
on cp-Ti, obtaining totally crack-free and dense layers, which
led to a decrease in the corrosion current densities of Ti-cp in
physiological solutions.221 Since ED is a low temperature
process it allowed for obtaining nanostructured coatings. The
nanopatterned surface together with the continuous Zn2+
release results in good osteoblast proliferation, and promoted
ALP expression in MC3T3-E1 preosteoblast cells.
The incorporation of bactericidal species into F-Hap also
provides interesting cationic–anionic combinations. Ag+ has
been incorporated into fluorapatite to fabricate hybrid coatings
with TiO2 nanotubes on Ti substrates.
222 The Ag/F-Hap coatings
form rod shaped nanoparticles that get into the voids of TiO2
nanotubes, thus increasing the adhesion strength of the coat-
ings. Fluoride incorporation also increases the dissolution
resistance whereas the presence of Ag+ killed all viable S. aureus
in the antibacterial tests. In addition, the hybrid coating
increased the corrosion resistance by two orders of magnitude
and showed high cell viability when MC3T3-E1 preosteoblasts
were cultured on it.
Co-substitution can only occur to a limited extent as it
causes crystal-chemical disorders that result in apatite decom-
position and segregation of other phases. Research interest has
been focused on preparing multimaterial coatings made of
singly substituted Haps. Using production techniques that
provide accurate control of the deposition pattern such as drop
on demand microdispensing, the distribution of singly sub-
stituted HAPs can be designed in a homogeneous or controlled
manner.224 Multimaterial coatings have been prepared by Lim
et al.225 by means of depositing Si-Hap and Ag-Hap on glass
substrates previously coated with a Hap layer. Interestingly the
homogeneous distribution of Ag-Hap at every alternate position
in the Si-Hap/Ag-Hap coating prevented S. aureus adhesion to
the same extent as the pure Ag-Hap coating, even though 50%
of Ag-Hap was replaced by Si-Hap. This result evidences the
importance of the homogeneity and pattern deposition of Ag+
in the coating, although the total elimination of bacteria was
not achieved in any case. On the other hand, the osteogenic
response of the Si-Hap/Ag-Hap coating was significantly lower
than the pure Si-Hap coating, indicating that the stimulatory
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5. In vivo studies of substituted
hydroxyapatite coatings
In vivo animal models have been used to determine funda-
mental features of substituted HAp coatings such as bone
regeneration at the peri-implant site, bone adhesion, angiogen-
esis, etc., which allows for determining the potential advan-
tages provided by the ions incorporated in HAp. Table 4 shows
the different ionic substitutions incorporated into HAp coat-
ings, together with the expected biological outcomes and the
animal models that they have been tested with. Zhao et al.
studied the effects of Mg in Mg-HAp coatings on the osseointe-
gration of dental implants.226 These authors observed
enhanced in vitro cell proliferation, higher ALP activity and
more osteocalcin production compared to pure HAp. However,
only temporary effects could be identified in vivo. A slightly
higher bone implant contact (BIC) for the Mg-HAp coatings was
observed 2 weeks after implantation, whereas no significant
differences were observed with respect to BIC or the amount of
bone between threads after 4 and 8 weeks.
Ke et al. incorporated MgO and SiO2 within plasma sprayed
hydroxyapatite coatings on titanium implants.227 The MgO/
SiO2-HAp coatings exhibited increased osteogenesis, osteointe-
gration and bone mineralization compared with non-
substituted HAp after implantation in rats’ femurs. More
interestingly, the pushout tests evidenced that the MgO/SiO2-
HAp coatings exhibited a shear modulus much higher than
uncoated and HAp coated implants (96% and 56.4%, respec-
tively), demonstrating the better quality of the bone–implant
interface for these coatings in a quantitative way. More recently,
the same group coated Ti and Ti6Al4V implants with a ternary
dopant system within HAp.228 This system was aimed at indu-
cing osteogenesis, angiogenesis and infection control by means
of ZnO, SiO2 and Ag2O incorporation, respectively. For this
study, these authors used the same rat femur model, eviden-
cing that the Zn/Si/Ag-HAp coating led to higher bone for-
mation at the early stage as well as more mineralization
compared with non-substituted HAp coatings. The Zn/Si/Ag-
HAp coatings resulted in better osteointegration with higher
shear modulus during the push out tests, although no evidence
of angiogenesis or antibacterial properties was demonstrated
in vivo.
Early degradation of substituted HAp coatings prepared by
low temperature methods is one of the most serious concerns
for transferring these devices to clinical applications. This is
the case of C-HAp coatings prepared by biomimetic methods.
Measuring the coating degradation within bone involves cer-
tain difficulties that can be partially overcome using ectopic
models. For instance, Barrère et al.229 implanted Ti6Al4V pieces
biomimetically coated with C-HAp, using a subcutaneous rat
model to determine the coating degradation and the biological
behavior derived from the solubility of the coatings. Interest-
ingly a dissolution–precipitation mechanism took place under
in vitro conditions with immersion time in a-MEM. However,
in vivo studies showed that no dissolution occurred of the C-
HAp coating. On the contrary, coating calcification could be
observed on these implants.
F-HAp coatings can be considered as an alternative to HAp
for avoiding early coating degradation. For instance, plasma
sprayed F-HAp coatings on Ti6Al4V do not degrade after 12 and
25 weeks of being implanted into the femora and humeri of
adult goats, whereas HAp coatings showed extensive degrada-
tion for the same period.230 Other studies confirmed these
observations by evidencing an almost equal degree of bone
apposition for plasma sprayed HAp and F-HAp coatings, but
less F-HAp coating dissolution within the first 3 months of
implantation.231,232 Studies on a goat maxilla model obtained
similar results, as no significant differences were found in the
histomorphometrical analysis between F-HAp and HAp coated
implants, although higher coating thickness reduction was
observed for pure HAp coatings.233
Osteoporotic animal models are very convienient for the
evaluation of substituted HAp coatings aimed at treating
patients having bones of low quality. Ovariectomized animal
models are often used for these studies since they mimic the
osteoporosis conditions in humans. Sr-HAp coatings have been
proposed for application in osteoporotic conditions and
implanted in the femur of ovariectomized rats.234 Different
amounts of Sr were incorporated in HAp, but the Sr-HAp
coatings with the highest Sr content led to the highest bone
formation. Biomechanical tests demonstrated the beneficial
effects of coatings with 20 mol% of Sr substitution on implant
fixation with respect to 5%, 10% and 0% Sr-HAp coatings,


























Table 3 Co-substituted Hap coatings
Coating Function Substrate Fabrication method Ref.
Ag/Sr-HAp Antibacterial/osteoblast function Titanium Hydrothermal method 208 and 209
Cu/Zn-HAp Antibacterial/biocompatibility/corrosion resistance Titanium Electrodeposition 211
Cu/Sr-HAp Antibacterial/osteoblast function Titanium Electrodeposition 212
Mg/Sr- HAp Mechanical properties/osteoblast function Ti6Al4V Plasma spraying 213
Ti40Nb Electrochemical deposition 214
Sm/Gd-HAp Antibacterial/corrosion resistance Stainless steal Electrodeposition 219
Co/F-HAp Angiogenesis/osteogenesis Culture plates Biomimetic method 220
Zn/F-HAp Corrosion resistance/osteogenesis Titanium Electrodeposition 221
Ag/F-HAp Coating stability/adhesion strength/antibacterial Titanium Electrodeposition 222
Si-HAp/Ag-HAp Osteogenesis/antibacterial Glass Drop on demand microdispensing 225
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Sr-HAp and Si-HAp coatings have been also deposited by
using biomimetic methods on screw-shaped implants and
placed in the tibia metaphysis of rats.235 The association of
small amounts of Si and Sr with these coatings improves the
bioactive behavior, especially at the very early stages after
implantation. Si seems to stimulate bone apposition, whereas
Sr fosters bone formation in the area within the threads. These
positive effects of Sr and Si cosubstitution in CaP coatings have
been recently confirmed by Bose et al.236 This group prepared
Si–Sr CaP coatings on Ti cylinders previously coated with TiO2
nanotubes by electrochemical anodization, a technique pre-
viously developed by the same group.237 In agreement with
previous work, these researchers could demonstrate that Sr and
Si substitution in CaP coatings led to an increase of osteoid
formation around the implant in the early stages (4 weeks) after
implantation in the distal femur of rats.
6. In vivo studies of scaffolds coated
with substituted-HAp
Traditionally, HAp based coatings have been aimed at improv-
ing the bone adhesion of solid implantable devices (prosthesis
stems, dental implants, fixation screws, etc.) designed for bone
substitution or fixation applications. An alternative to the
current substitutive strategies in the treatment of bone defects
is the concept of functionalized metallic macroporous
scaffolds.238 These scaffolds must facilitate osteogenesis and
new blood vessel formation within their macroporous struc-
ture, while exhibiting optimal mechanical behavior. Both
aspects are mandatory for bone regeneration of critical defects,
particularly in osteoporotic bones, where the implant integra-
tion with the hosting bone is seriously affected due to the low
bone formation rate in the peri-implant region.239 The surface
functionalization of these metal structures with a highly bioac-
tive bioceramic has emerged as a very interesting
alternative.240,241
The preparation of Si-HAp coatings by low temperature
methods and their in vivo evaluation have been carried out by
several research groups.242,243 For this aim Ti or Ti alloy
macroporous scaffolds have been often chosen as substrates.
Zhang et al.242 proposed Ti scaffolds prepared by fiber sintering
coated with Si-HAp by a biomimetic method. The scaffolds
exhibited a porosity of 67% with a pore size of 150–600 mm.
This study compared uncoated Ti scaffolds with pure HAp
coated Ti and Si-HAp coated scaffolds when implanted in
New Zealand rabbits. Both the HAp and Si-HAp coatings led
to a significant increase of the bone ingrowth rate compared to
uncoated Ti, evidencing that both coatings enhanced the
osteoconductive properties. Moreover, the Si-HAp coated scaf-
folds exhibited significantly higher bone ingrowth than the
HAp coated scaffolds. After four weeks, 90% of the pore area
was covered by new bone tissue, evidencing the positive role of
Si substitution in this kind of coatings.
Recently, Si-HAp coatings prepared by a sol–gel route on
Ti6Al4V macroporous scaffolds have demonstrated a synergis-
tic effect when they are associated with vascular endothelial
growth factor (VEGF) in Q16osteoporotic sheep244 (Fig. 2). Ti6Al4V
macroporous structures were fabricated by electron beam melt-
ing to obtain customized highly macroporous structures, which
were coated with Si-HAp by the dip coating method. Subse-
quently, VEGF was immobilized on the coatings by soaking the
specimens in a solution of VEGF in a phosphate buffered
solution. In vitro studies demonstrated that the SiHAp coatings
stimulated the proliferation of MC3T3-E1 pre-osteoblastic cells,
whereas the adsorption of VEGF stimulates the proliferation of
EC2 mature endothelial cells. When these scaffolds were

























Table 4 In vivo studies carried out with substituted HAp coatings
Coating Substrate Fabrication method In vivo animal model Ref.
Ag-HAp Titanium Thermal spraying Rat, subcutaneous 117
Mg-HAp Ti, Ti6Al4V Electrochemical deposition Rabbit, bone 226
Ti6Al4V Pulsed laser deposition Rabbit, bone 245
Titanium Plasma spraying Rat, bone 227
Sr-HAp Titanium Electrochemical deposition Rat, bone 234
Titanium (oxidized) Biomimetic method 235
Si-HAp Titanium (oxidized) Biomimetic method Rat, bone 235
Porous titanium Biomimetic method Rabbit, bone 242
Porous titanium Precipitation method Rabbit, bone 243
Porous Ti6l4V Dip coating Sheep, bone 244
F-HAp Ti6Al4V Plasma spraying Goat, bone 230 and 231
Ti6Al4V Plasma spraying Rabbit, bone 232
Titanium Plasma spraying Goat, bone 233
C-HAp Ti6Al4V Biomimetic method Rat, subcutaneous 229
Sr/SiHAp Porous titanium Biomimetic method Rat, bone 236
Zn/Si/Ag-HAp Ti, Ti6Al4V Plasma spraying Rat, bone 228
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presence of the SiHAp coating and VEGF led to a significant
increase of new tissue formation in osteoporotic bone, demon-
strating that, under osteoporotic conditions, both osteogenesis
and vascularization must be strengthened to reach bone regen-
eration within these metallic scaffolds.
Mg-HAp coatings on porous implants also enhance both
early and long-term osteogenesis. Mróz et al.245 have prepared
Mg-HAp and Mg-substituted octacalcium phosphate coatings
by PLD on porous titanium-based implants. When these porous
scaffolds were implanted in a rabbit femoral model for 6
months, the histopathological analysis revealed that all the
implants, the coated ones and the uncoated reference, were
biocompatible, exhibiting bone ingrowth within the pores.
However, microCT analysis evidenced a significantly higher
bone volume for implants coated with Mg-HAp compared to
the uncoated andQ17 Mg-OCP coatings. Unfortunately, this work
did not include a group of pure HAp coated implants to
establish the positive role of Mg at long-term implantation
stages.
7. Summary and future perspectives
Substituted HAp coatings provide a very interesting alternative
to improve the performance of dental and orthopedic implants.
The different ionic substitutions allowed by the HAp structure,
together with the variety of fabrication methods, provide new
characteristics to the commercially available plasma sprayed
CaP coatings. For instance, Si-HAp coatings deposited on
porous metallic implants have shown excellent bone regenera-
tion capabilities through the synergy of osteoconductive HAp
with the osteoinductive behavior of the soluble silica species
released from the coatings. Other ionic substituents like Sr2+,
Mg2+ or Zn2+ stimulate bone healing and are expected to
provide relevant advances for the treatment of osteoporotic
fractures.
Infection is also a serious cause of orthopedic implant
failure. Thousands of metallic orthopedic prostheses are
revised every year because of infections caused by S. aureus
and S. epidermidis. In this sense, the incorporation of ions with
antimicrobial properties to lower the Q18risk of infection has
become a priority research field for the development of new
coatings. Substitutions with Ag+ and Cu2+ have evidenced
positive in vitro results with bacterial strains. However, in vivo
studies are very scarce, perhaps because of the difficulty in
designing appropriate in vivo infection models in bone. The
development of these models will be mandatory for the further
development of these devices. Other biological activities such
as angiogenesis or antitumoral properties can be obtained by
the incorporation of Co2+ or SeO3
2, although much more
in vitro and in vivo evidence is required before being translated
into clinical applications.
The association of drugs and osteogenic macromolecules
with substituted HAp coatings has opened new possibilities for
the treatment of bone pathologies. Some attempts have been
carried out involving the antiosteoporotic activity of Sr2+ in
combination with zoledronate acid246 or providing complemen-
tary therapeutic effects with the antibiotic activity of
vancomycin.247 Substituted HAp coatings combined with bio-
logical entities provide great potential to improve new bone
formation at the peri-implant site or bone regeneration in
macroporous scaffolds. The combination of Mg substituted b-
TCP and C-HAp with recombinant human bone morphogenetic
protein-2 (rhBMP-2) has shown excellent behavior with respect
to rhBMP-2 delivery, which resulted in superior bone formation
within scaffolds.248 The increasing knowledge about the syner-
gies of substituted HAp with proteins,249 growth factors,244 or
microRNAs250 will eventually result in customized coatings for
each specific clinical challenge.
The incorporation of rapid prototyping methods as a new
strategy for coating fabrication is called to Q19play a fundamental
role in this field. Techniques such as drop on demand micro-
dispensing allow coating customization, distributing at the
micrometer scale different substituted HAp. These techniques
also provide new tools for incorporation and controlled release
of drugs from the coating to the local environment. However,
all these possibilities will be carried out successfully only if
appropriate in vivo animal models (osteoporotic, infection,
tumoral, etc.) are previously developed.
Transferring new biomedical devices from the lab to clinical
applications is a difficult challenge. Coatings are not an excep-
tion. As an estimative approximation, one technology project
out of ten results in a biomedical device that goes to the clinical
trial phase.251 Innovation in the biomaterials industry is com-
monly technology driven but always to satisfy unmet clinical
needs. In this sense, the large amount of scientific literature
evidences that research on new coatings is widely supported by
technology development. There are many fabrication methods
that allow for manufacturing substituted hydroxyapatite coat-

























Fig. 2 Implantation of a macroporous Ti6Al4V scaffold coated with Si-
HAp/VEGF in an osteoporotic sheep model (a). Computed tomography
scan image of the implant within the bone defect (b). Histological overview
of bones implanted with uncoated Ti6Al4V microporous implants (c) and
SiHAp/VEGF coated implants (d).
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Certainly, improving coating adhesion and reducing the costs
related to industrial upscaling can be considered as the critical
issues for spreading the application of novel coatings.252,253 But
accelerating early bone–implant integration and the treatment
and/or prevention of prothesis infection remain as unmet
clinical needs that must be also satisfied. The variety of
production techniques and compositions should play a relevant
role in transferring new substituted HAp coatings to clinical
practice. However, the current scenario largely differs from this.
Only a few CaP bioceramics fabricated by plasma spraying are
commercially available. The causes of this lack of translation
can be found in different aspects. Firstly, in vivo studies
concerning substituted HAp coatings are very scarce, which is
partially caused by the lack of appropriate animal models. One
of the most relevant clinical needs is to avoid prosthesis
infection and different cationic substitutions have been intro-
duced in HAp coatings. However, there are not any in vivo
studies including a bone infection model to test these devices,
and only some subcutaneous models have been proposed.
The second hurdle is the regulatory processes toward market
approval. In this sense new substituted HAp coatings fabricated
with alternative technologies to plasma spraying are considered
as devices that do not have any equivalent on the market. In
these cases, pre-market approval (PMAs) is compulsory, which
increases the financial and time costs compared to products
having equivalent ones in the market, which just require 510k
notification. This fact would make novel coatings less attractive
to investors, especially because the biggest hurdle can come at
the very end of the process with the clinical trials, when a large
part of the investment has been already made.
In conclusion, commercial translation of substituted HAp
coatings is not exclusively driven by the available technology.
Evidence-based definition of the unmet clinical need and pre-
clinical studies with appropriate animal models are mandatory
to reduce the failure risk during clinical trials. In addition,
regulatory filing and an effective marketing strategy would be
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M. Epple, E. Gómez-Barrena, A. Herrera, J. A. Planell,
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